Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Dizal Pharmaceutical

Evaluate

Thumbnail
July 14, 2023

Theseus’s Asco disappointment bites

June 28, 2023

Black Diamond’s lung cancer pivot delivers

The company’s stock surges 236% on first data with its new EGFR project, so where’s the catch?

Article image
Vantage logo
June 09, 2023

Asco 2023 story roundup

Article image
Vantage logo
June 08, 2023

Asco 2023 movers – maintaining the momentum

Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.

Article image
Vantage logo
June 06, 2023

Asco 2023 – Dizal heralds a “super-Tagrisso”

China’s Dizal, an unexpected targeted therapy star of Asco 2021, is back with even more impressive data.

Article image
Vantage logo
August 10, 2022

After Astra’s exit Zentalis doubles down on Wee1

Article image
Vantage logo
May 12, 2022

Market crash throws up a rich deal for Cullinan

Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.

Article image
Vantage logo
March 29, 2022

Cullinan bids to upstage Takeda and J&J

Article image
Vantage logo
November 30, 2021

Blueprint takes a long shot at a small niche

Article image
Vantage logo
September 17, 2021

Esmo 2021 – poziotinib could add first-line string to its bow

Article image
Vantage logo
September 03, 2021

World Lung 2021 preview – China challenges and tremelimumab rises

The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up